California State Teachers Retirement System Has $39.70 Million Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

California State Teachers Retirement System cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 0.8% in the third quarter, HoldingsChannel reports. The institutional investor owned 198,351 shares of the biopharmaceutical company’s stock after selling 1,620 shares during the quarter. California State Teachers Retirement System’s holdings in Alnylam Pharmaceuticals were worth $39,702,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Guardian Wealth Advisors LLC bought a new stake in Alnylam Pharmaceuticals in the third quarter valued at $27,000. Allworth Financial LP boosted its stake in shares of Alnylam Pharmaceuticals by 708.7% in the 3rd quarter. Allworth Financial LP now owns 186 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 163 shares in the last quarter. SeaCrest Wealth Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $44,000. CI Investments Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 52.7% in the 3rd quarter. CI Investments Inc. now owns 394 shares of the biopharmaceutical company’s stock worth $79,000 after purchasing an additional 136 shares during the last quarter. Finally, Alta Advisers Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $80,000.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $240.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, February 24th. EF Hutton Acquisition Co. I initiated coverage on Alnylam Pharmaceuticals in a report on Tuesday, February 21st. They set a “buy” rating and a $304.00 price target for the company. Citigroup reduced their price objective on Alnylam Pharmaceuticals from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, February 24th. Canaccord Genuity Group lowered their target price on Alnylam Pharmaceuticals from $310.00 to $291.00 and set a “buy” rating for the company in a research note on Friday, February 24th. Finally, HC Wainwright reiterated a “buy” rating and set a $415.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, March 3rd. Seven investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $244.26.

Insiders Place Their Bets

In related news, CMO Pushkal Garg sold 18,072 shares of the company’s stock in a transaction on Friday, March 3rd. The shares were sold at an average price of $200.00, for a total value of $3,614,400.00. Following the completion of the sale, the chief marketing officer now owns 4,345 shares in the company, valued at approximately $869,000. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Alnylam Pharmaceuticals news, EVP Indrani Lall Franchini sold 1,675 shares of the firm’s stock in a transaction that occurred on Thursday, February 2nd. The shares were sold at an average price of $226.01, for a total transaction of $378,566.75. Following the sale, the executive vice president now directly owns 3,500 shares in the company, valued at approximately $791,035. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CMO Pushkal Garg sold 18,072 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, March 3rd. The shares were sold at an average price of $200.00, for a total transaction of $3,614,400.00. Following the completion of the transaction, the chief marketing officer now directly owns 4,345 shares in the company, valued at approximately $869,000. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 2.2 %

NASDAQ ALNY opened at $185.45 on Friday. The company has a current ratio of 3.51, a quick ratio of 3.34 and a debt-to-equity ratio of 3.85. Alnylam Pharmaceuticals, Inc. has a 12 month low of $117.58 and a 12 month high of $242.97. The company has a market capitalization of $23.02 billion, a PE ratio of -20.42 and a beta of 0.49. The stock has a 50-day simple moving average of $213.89 and a 200 day simple moving average of $213.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last announced its quarterly earnings results on Thursday, February 23rd. The biopharmaceutical company reported ($1.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.13) by $0.45. Alnylam Pharmaceuticals had a negative net margin of 109.04% and a negative return on equity of 1,287.80%. The business had revenue of $335.04 million for the quarter, compared to the consensus estimate of $312.45 million. During the same period last year, the company posted ($2.16) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 29.6% on a year-over-year basis. Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -6.93 EPS for the current year.

Alnylam Pharmaceuticals Profile

(Get Rating)

Alnylam Pharmaceuticals, Inc is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.